SEEL: חוב לטווח קצר של החברה Seelos Therapeutics

The price trajectory of Seelos Therapeutics (SEEL) correlates with strict FDA oversight and the protection of proprietary formulas for depression, with the indicator standing at 0.00. The business relies on the development of innovative ketamine-based treatments for CNS therapy. The team consists of leading neurobiologists who strive to overcome rare pathologies while maintaining broad research freedom.

Short-term debt measures the total liabilities with a maturity of up to one year, reflecting current liquidity and the company's ability to service operational loans. By analyzing changes in short-term liabilities, an investor assesses the financial stability of Seelos Therapeutics (SEEL), where controlling short-term borrowing is critical to ensuring the continuous development of CNS molecules until their commercialization and transformation into a stable cash cow.